Skip to main content

Table 3 Artesunate–amodiaquine and artemether-lumefantrine efficacy on day 28 in Owando, Republic of Congo

From: Malaria burden and anti-malarial drug efficacy in Owando, northern Congo

  ASAQ AL
No. of included patients (intention-to-treat) 62 61
PCR-uncorrected responses on day 28
 Withdrawn or lost to follow up: N; % (95 % CI) 7; 11.3 (4.7–21.9) 9; 14.8 (7.0–26.2)
 Per protocol population: N; % (95 % CI) 55; 88.7 (78.1–95.3) 52; 85.2 (73.8–93.0)
 Failures: N; % (95 % CI) 4; 7.3 (2.0–17.6) 4; 7.7 (2.1–18.5)
 ETF: N; % (95 % CI) 0; 0 (0–5.8) 1; 1.9 (0–10.3)
 LCF: N; % (95 % CI) 1; 1.8 (0–9.7) 1; 1.9 (0–10.3)
 LPF : N; % (95 % CI) 3; 5.5 (1.1–15.1) 2; 3.8 (0.5–13.2)
 ACPR: N; % (95 % CI) 51; 92.7 (82.4–98.0) 48; 92.3 (81.5–97.9)
PCR-corrected responses on day 28
 Withdrawn + lost-to-follow-up + censured due to new infections: N; % (95 % CI) 11; 17.7 (9.2–29.5) 12; 19.7 (10.6–31.8)
 Per protocol population: N; % (95 % CI) 51; 82.3 (70.5–90.8) 49; 80.3 (68.2–89.4)
 ETF: N; % (95 % CI) 0; 0 (0–7.0) 1; 2.0 (0.1–10.9)
 Recrudescence: N; % (95 % CI) 0; 0 (0–7.0) 0; 0 (0–7.2)
 ACPR: N; % (95 % CI) 51; 100 (93.0–100) 48; 98.0 (89.1–99.9)
 New infections: n/N (%) 4/4 (100) 3/3 (100)
  1. PCR polymerase chain reaction, 95 % CI 95 % confidence interval, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, * n/N number of new infections divided by number of samples analysed by PCR